Novartis Institute Marries Robotics, Cell-Based Assays to Accelerate Library Profiling for Pharma

The development is significant because GNF straddles the border between industry and academia, and its work may provide a blueprint for the growing number of pharmaceutical and academic scientists wishing to scale up the throughput, automation, and multiplexing capabilities of cell-based drug screening. Subscribers: click headline for more

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.